CardioGenics Holdings Inc
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market. Its products include QL Care Analyzer, which is a portable, stand-alone, and automated POC immunoanalyzer; a series of immunoassay tests to enhance the management of patients with cardiovascular diseases; and paramagnetic beads that are used as a sol… Read more
CardioGenics Holdings Inc (CGNH) - Net Assets
Latest net assets as of January 2016: $-1.79 Million USD
Based on the latest financial reports, CardioGenics Holdings Inc (CGNH) has net assets worth $-1.79 Million USD as of January 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($558.45K) and total liabilities ($2.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.79 Million |
| % of Total Assets | -319.91% |
| Annual Growth Rate | N/A |
| 5-Year Change | -164.87% |
| 10-Year Change | N/A |
| Growth Volatility | 786.38 |
CardioGenics Holdings Inc - Net Assets Trend (2000–2015)
This chart illustrates how CardioGenics Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CardioGenics Holdings Inc (2000–2015)
The table below shows the annual net assets of CardioGenics Holdings Inc from 2000 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-10-31 | $-1.56 Million | -35.32% |
| 2014-10-31 | $-1.16 Million | -25.95% |
| 2013-10-31 | $-917.04K | -80.96% |
| 2012-10-31 | $-506.75K | -121.03% |
| 2011-10-31 | $2.41 Million | +26.41% |
| 2010-10-31 | $1.91 Million | -2.96% |
| 2009-10-31 | $1.96 Million | +1822.97% |
| 2008-10-31 | $102.14K | +100.70% |
| 2007-10-31 | $-14.64 Million | -225.62% |
| 2006-10-31 | $-4.50 Million | -237.65% |
| 2005-10-31 | $-1.33 Million | -430.66% |
| 2004-10-31 | $402.67K | +751.49% |
| 2003-10-31 | $-61.81K | +95.03% |
| 2002-10-31 | $-1.24 Million | -899.69% |
| 2001-10-31 | $155.56K | -91.91% |
| 2000-10-31 | $1.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CardioGenics Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3168007000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.14K | % |
| Other Comprehensive Income | $151.80K | % |
| Other Components | $47.84 Million | % |
| Total Equity | $-1.56 Million | 100.00% |
CardioGenics Holdings Inc Competitors by Market Cap
The table below lists competitors of CardioGenics Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WEST3F
SA:WEST3F
|
$9.62K |
|
TENAX INTL SPA
F:7IH
|
$9.62K |
|
Genxone SA
WAR:GX1
|
$9.62K |
|
Inbest Prime VII Inmuebles SOCIMI S.A.
MC:YINB7
|
$9.64K |
|
KUNLUN ENERGY
MU:CTJ1
|
$9.60K |
|
QuantumKore Inc
PINK:SBOX
|
$9.60K |
|
ITV - Dusseldorf Stock Exchang
DU:IJ7
|
$9.60K |
|
Brera Holdings PLC
NASDAQ:SLMT
|
$9.59K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CardioGenics Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from -1,155,058 to -1,562,991, a change of -407,933.
- Net loss of 1,916,324 reduced equity.
- Other comprehensive income increased equity by 175,759.
- Other factors increased equity by 1,332,632.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.92 Million | -122.61% |
| Other Comprehensive Income | $175.76K | +11.25% |
| Other Changes | $1.33 Million | +85.26% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CardioGenics Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-10-31 | $1.35 | $0.00 | x |
| 2001-10-31 | $0.09 | $0.00 | x |
| 2002-10-31 | $-0.47 | $0.00 | x |
| 2003-10-31 | $-0.02 | $0.00 | x |
| 2004-10-31 | $0.09 | $0.00 | x |
| 2005-10-31 | $-0.30 | $0.00 | x |
| 2006-10-31 | $-1.05 | $0.00 | x |
| 2007-10-31 | $-3.15 | $0.00 | x |
| 2008-10-31 | $0.02 | $0.00 | x |
| 2009-10-31 | $0.06 | $0.00 | x |
| 2010-10-31 | $0.04 | $0.00 | x |
| 2011-10-31 | $0.05 | $0.00 | x |
| 2012-10-31 | $0.00 | $0.00 | x |
| 2013-10-31 | $-0.01 | $0.00 | x |
| 2014-10-31 | $-0.02 | $0.00 | x |
| 2015-10-31 | $-0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CardioGenics Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1034.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -866.49% | -1599.15% | 0.24x | 2.22x | $-16.86 Million |
| 2001 | -10713.36% | -1664.09% | 1.67x | 3.85x | $-16.68 Million |
| 2002 | 0.00% | -643.67% | 4.17x | 0.00x | $-3.90 Million |
| 2003 | 0.00% | -668.27% | 0.72x | 0.00x | $-2.57 Million |
| 2004 | -498.08% | -791.94% | 0.50x | 1.26x | $-2.05 Million |
| 2005 | 0.00% | -788.30% | 0.29x | 0.00x | $-1.76 Million |
| 2006 | 0.00% | -2181.78% | 0.29x | 0.00x | $-3.19 Million |
| 2007 | 0.00% | -5792.41% | 1.51x | 0.00x | $-10.31 Million |
| 2008 | -2772.63% | -1599.39% | 0.40x | 4.34x | $-2.84 Million |
| 2009 | -1472.80% | -134303.28% | 0.01x | 1.47x | $-29.12 Million |
| 2010 | -92.09% | 0.00% | 0.00x | 1.13x | $-2.24 Million |
| 2011 | -142.08% | -43650.02% | 0.00x | 1.05x | $-4.15 Million |
| 2012 | 0.00% | -100851.89% | 0.00x | 0.00x | $-1.29 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.86 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.56 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.76 Million |
Industry Comparison
This section compares CardioGenics Holdings Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CardioGenics Holdings Inc (CGNH) | $-1.79 Million | -866.49% | N/A | $9.61K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |